Trabectedin, a drug mainly used for soft tissue malignancies, inhibits TAMs, enhancing anti-cancer adaptive immunity in response to anti-programmed cell death protein 1 (PD-1) treatment [83]. This evidence concerns the gene PDCD1 and cancer.